Now showing items 1-13 of 13

    • Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax 

      Montero, Joan; Stephansky, Jason; Cai, Tianyu; Griffin, Gabriel Kenneth; Cabal-Hierro, Lucia; Togami, Katsuhiro; Hogdal, Leah J.; Galinsky, Ilene; Morgan, Elizabeth Amy; Aster, Jon Christopher; Davids, Matthew Steven; Leboeuf, Nicole Renee; Stone, Richard Maury; Konopleva, Marina; Pemmaraju, Naveen; Letai, Anthony George; Lane, Andrew Alan (American Association for Cancer Research (AACR), 2016)
      Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy with dismal outcomes for which no standard therapy exists. We found that primary BPDCN cells were dependent on the anti-apoptotic ...
    • Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances 

      Liu, Xiaochuan; Wang, Aoli; Liang, Xiaofei; Chen, Cheng; Liu, Juanjuan; Zhao, Zheng; Wu, Hong; Deng, Yuanxin; Wang, Li; Wang, Beilei; Wu, Jiaxin; Liu, Feiyang; Fernandes, Stacey M.; Adamia, Sophia; Stone, Richard M.; Galinsky, Ilene A.; Brown, Jennifer R.; Griffin, James D.; Zhang, Shanchun; Loh, Teckpeng; Zhang, Xin; Wang, Wenchao; Weisberg, Ellen L.; Liu, Jing; Liu, Qingsong (Impact Journals LLC, 2016)
      PI3Kδ is predominately expressed in leukocytes and has been found overexpressed in B-cell related malignances such as CLL and AML. We have discovered a highly selective ATP competitive PI3Kd inhibitor PI3KD-IN-015, which ...
    • Detecting T-cell Reactivity to Whole Cell Vaccines 

      Brusic, Ana; Hainz, Ursula; Wadleigh, Martha; Neuberg, Donna; Su, Mei; Canning, Christine M.; DeAngelo, Daniel J.; Stone, Richard M.; Lee, Jeng-Shin; Mulligan, Richard C.; Ritz, Jerome; Dranoff, Glenn; Sasada, Tetsuro; Wu, Catherine J. (Landes Bioscience, 2012)
      BCR-ABL\(^+\) K562 cells hold clinical promise as a component of cancer vaccines, either as bystander cells genetically modified to express immunostimulatory molecules, or as a source of leukemia antigens. To develop a ...
    • Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML 

      Wang, Aoli; Wu, Hong; Chen, Cheng; Hu, Chen; Qi, Ziping; Wang, Wenchao; Yu, Kailin; Liu, Xiaochuan; Zou, Fengming; Zhao, Zheng; Wu, Jiaxin; Liu, Juan; Liu, Feiyang; Wang, Li; Stone, Richard M.; Galinksy, Ilene A.; Griffin, James D.; Zhang, Shanchun; Weisberg, Ellen L.; Liu, Jing; Liu, Qingsong (Impact Journals LLC, 2016)
      The FLT3-ITD mutation is one of the most prevalent oncogenic mutations in AML. Several FLT3 kinase inhibitors have shown impressive activity in clinical evaluation, however clinical responses are usually transient and ...
    • An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome 

      Galili, Naomi; Tamayo, Pablo; Bosco, Jocelyn; Ladd-Acosta, Christine; Raza, Azra; Ebert, Benjamin L.; Mak, Raymond Heungwing; Pretz, Jennifer Lee; Tanguturi, Shyam Kumar; Stone, Richard Maury; Golub, Todd R. (Public Library of Science, 2008)
      Background: Lenalidomide is an effective new agent for the treatment of patients with myelodysplastic syndrome (MDS), an acquired hematopoietic disorder characterized by ineffective blood cell production and a predisposition ...
    • MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia 

      Tagde, Ashujit; Rajabi, Hasan; Stroopinsky, Dina; Gali, Reddy; Alam, Maroof; Bouillez, Audrey; Kharbanda, Surender; Stone, Richard; Avigan, David; Kufe, Donald (Impact Journals LLC, 2016)
      Aberrant DNA methylation is a hallmark of acute myeloid leukemia (AML); however, the regulation of DNA methyltransferase 1 (DNMT1), which is responsible for maintenance of DNA methylation patterns, has largely remained ...
    • Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells 

      Bhanot, Haymanti; Reddy, Mamatha M.; Nonami, Atsushi; Weisberg, Ellen L.; Bonal, Dennis; Kirschmeier, Paul T.; Salgia, Sabrina; Podar, Klaus; Galinsky, Ilene; Chowdary, Tirumala K.; Neuberg, Donna; Tonon, Giovanni; Stone, Richard M.; Asara, John; Griffin, James D.; Sattler, Martin (2015)
      The rapid proliferation of myeloid leukemia cells is highly dependent on increased glucose metabolism. Through an unbiased metabolomics analysis of leukemia cells, we found that the glycogenic precursor UDP-D-glucose is ...
    • Putative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in pathogenesis of myeloid malignancies 

      Singh, H; Lane, A A; Correll, M; Przychodzen, B; Sykes, David Brian; Stone, Richard Maury; Ballen, K K; Amrein, Philip Crawford; Maciejewski, J; Attar, E C (Springer Nature, 2013)
    • Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing 

      Mandelker, Diana; Dal Cin, Paola; Jacene, Heather A.; Armand, Philippe; Stone, Richard M.; Lindeman, Neal I. (BioMed Central, 2015)
      Next generation sequencing (NGS) is increasingly being used clinically to characterize the molecular alterations found in patients’ tumors. These testing results have the potential to affect clinical care by guiding ...
    • Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells 

      Weisberg, Ellen; Liu, Qingsong; Zhang, Xin; Nelson, Erik; Sattler, Martin; Liu, Feiyang; Nicolais, Maria; Zhang, Jianming; Mitsiades, Constantine S; Smith, Robert Walsh; Stone, Richard; Galinsky, Ilene; Nonami, Atsushi; Griffin, James D.; Gray, Nathanael (Public Library of Science, 2013)
      Objectives: Tyrosine kinase inhibitor (TKI)-treated acute myeloid leukemia (AML) patients commonly show rapid and significant peripheral blood blast cell reduction, however a marginal decrease in bone marrow blasts. This ...
    • SYK Regulates mTOR Signaling in AML 

      Carnevale, Julia; Ross, Linda; Puissant, Alexandre; Banerji, Versha; Stone, Richard M.; DeAngelo, Daniel J.; Ross, Kenneth N.; Stegmaier, Kimberly (2014)
      Spleen Tyrosine Kinase (SYK) was recently identified as a new target in acute myeloid leukemia (AML); however, its mechanistic role in this disease is poorly understood. Based on the known interaction between SYK and mTOR ...
    • Targeting STAT5 in Hematologic Malignancies through Inhibition of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2 

      Liu, Suhu; Walker, Sarah Rebecca; Nelson, E; Cerulli, R.; Xiang, Michael; Toniolo, P. A.; Qi, Jun; Stone, Richard Maury; Wadleigh, Martha; Bradner, James Elliott; Frank, David Alan (American Association for Cancer Research (AACR), 2014)
      The transcription factor signal STAT5 is constitutively activated in a wide range of leukemias and lymphomas, and drives the expression of genes necessary for proliferation, survival, and self-renewal. Thus, targeting STAT5 ...
    • Targeting the Creatine Kinase Pathway in EVI1-Positive Acute Myeloid Leukemia 

      Fenouille, Nina; Bassil, Christopher; Ben-Sahra, Issam; Benajiba, Lina; Alexe, Gabriela; Ramos, Azucena; Pikman, Yana; Conway, Amy; Burgess, Michael; Li, Qing; Luciano, Frédéric; Auberger, Patrick; Galinsky, Ilene; DeAngelo, Daniel J.; Stone, Richard M.; Zhang, Yi; Perkins, Archibald; Shannon, Kevin; Hemann, Michael; Puissant, Alexandre (American Society of Hematology, 2017)
      Abnormal expression of the transcription factor EVI1 through chromosome 3q26 rearrangements has been implicated in the development of one of the most therapeutically challenging high-risk subtypes of acute myeloid leukemia ...